Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma

Oncogene

Volumn 14, Issue 5, 1997, Pages 603-609

  Arap, Wadih ^a,c   Knudsen, Erik S ^a   Wang, Jean Y J ^a   Cavenee, Webster K ^a,b   Huang, H J Su ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

CDKN2A; Glioma; Mutation; p16(INK4a); RB; Tumor suppressor gene

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ANIMAL CELL; ARTICLE; CHROMOSOME 9P; CONTROLLED STUDY; GENE REPRESSION; GLIOMA; GLIOMA CELL; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0031047550     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1200870     Document Type: Article

References (45)

1. Arap W et al. (1995). Cancer Res. 55, 1351-1354.
2. Caldas C et al. (1994) Nature Genet., 8, 27-32.
3. Cairns P et al. (1995). Nature Med., 11, 210-212.
4. Costello JF, Berger MS, Huang HJS and Cavenee WK. (1996). Cancer Res., 56, 2405-2410.
5. Duro D et al. (1995). Oncogene, 11, 21-29.
6. Fåhraeus R et al. (1996). Curr. Biol., 6, 84-91.
7. Furnari FB, Huang HJS and Cavenee WK. (1995). Cancer Surv., 25, 233-275.
8. Gianni C and Finocchiaro G. (1994). Cancer Res., 54, 6338-6339.
9. Goldstein AM et al. (1995). New Engl. J. Med., 333, 970-974.
10. Hannon GJ and Beach D. (1994). Nature, 371, 257-261.
11. He J et al. (1994). Cancer Res., 54, 5804-5807.
12. He J, Oison JJ and James CD. (1995). Cancer Res., 55, 4833-4836.
13. Herrin DL and Schmidt GW. (1988). Biotechniques, 6, 196-200.
14. James CD et al. (1993). Cancer Res., 53, 3674-3676.
15. Jen J et al. (1994). Cancer Res., 54, 6353-6358.
16. Kamb A et al. (1994). Science, 264, 436-440.
17. Kamb A. (1995). Trends Genet., 11, 136-140.
18. Knudson AG, Hethcote HW and Brown BW. (1975). Proc. Natl. Acad. Sci. USA, 72, 5116-5120.
19. Koh J, Enders GH, Dynlacht BD and Harlow E. (1995). Nature, 375, 506-510.
20. Kyritsis AP et al. (1995). Proc. Am. Ass. Cancer Res., 36, 582.
21. Kyritsis AP et al. (1996). Oncogene, 12, 63-67.
22. Li YJ et al. (1995). Oncogene, 11, 597-600.
23. Liu Q et al. (1995). Oncogene, 10, 1061-1070.
24. Louis DN, Seizinger BR and Cavenee WK. (1995). Benign Cerebral Gliomas. Apuzzo MLJ (ed). AANS publications: Lebanon, NH, pp. 163-180.
25. Lukas J et al. (1995). Nature, 375, 503-506.
26. Mao L et al. (1995). Cancer Res., 55, 2995-2997.
27. Merlo A et al. (1995). Nature Med., 1, 686-692.
28. Moulton T et al. (1995). Am. J. Pathol., 146, 613-619.
29. Nishikawa R et al. (1995). Cancer Res., 55, 1941-1945.
30. Nobori T et al. (1994). Nature, 368, 753-756.
31. Nowell PC. (1976). Science, 194, 23-28.
32. Olopade OI et al. (1992). Cancer Res., 52, 2523-2529.
33. Parry D and Peters G. (1996). Mol. Cell. Biol., 16, 3844-3852.
34. Qin XQ, Chittenden T, Livingston DM and Kaelin WG Jr. (1992). Genes Dev., 6, 953-964.
35. Quelle DE, Zindy F, Ashmun RA and Sherr CJ. (1995). Cell, 83, 993-1000.
36. Ranade K et al. (1995). Nature Genet., 10, 114-116.
37. Schmidt EE, Ichimura K, Reifenberger G and Collins VP. (1994). Cancer Res., 54, 6321-6324.
38. Serrano M, Hannon GJ and Beach D. (1993). Nature, 366, 704-707.
39. Sidransky D et al. (1992). Nature, 355, 846-847.
40. Stone S et al. (1995). Cancer Res., 55, 2988-2994.
41. Ueki K et al. (1994). Hum. Mol. Genet., 3, 1841-1845.
42. van den Heuvel S and Harlow E. (1993). Science, 262, 2050-2054.
43. Walker DG et al. (1995). Cancer Res., 55, 20-23.
44. Welch PJ and Wang JY. (1993). Cell, 75, 779-790.
45. Yang R, Gombart AF, Serrano M and Koeffler HP. (1995). Cancer Res., 55, 2503-2506.